Echocardiographic phenotypes of opioid-induced cardiotoxicity: a narrative review

Opioid cardiotoxicity is an increasing clinical concern, yet its echocardiographic manifestations are heterogeneous and poorly characterized. This narrative review synthesizes available evidence, maps the principal echocardiographic phenotypes of opioid-related cardiac injury, and identifies major knowledge gaps. A structured PubMed search (January 2014-December 2024) combined opioid and echocardiographic terms without language restriction. Human and animal studies of any design assessing cardiac structure or function by echocardiography after acute or chronic opioid exposure were eligible. Of 209 records, 41 were included and grouped by dominant phenotype. No formal protocol (e.g., PRISMA) or risk-of-bias appraisal was applied. Five distinct—and often conflicting—phenotypes emerged: (1) severe, potentially reversible global left ventricular systolic dysfunction (LVEF as low as 20%), sometimes progressing to cardiogenic shock yet normalising within 48–72 h; (2) Takotsubo cardiomyopathy, classic after withdrawal and predominantly reverse after intoxication; (3) right ventricular dysfunction with pulmonary hypertension, usually secondary to hypoxia or left-sided failure but occasionally isolated; (4) consistent cardioprotection in animal ischaemia–reperfusion models, unsupported by any prospective human echocardiographic study; and (5) a mechanically normal profile despite QTc exceeding 610 ms and torsades de pointes. Phenotypes 1–3 rest largely on case reports, and many studies are confounded by co-administered cocaine, benzodiazepines or α2-adrenoceptor agonists. Opioid cardiac effects are context-dependent, and mechanical toxicity diverges from electrical toxicity: a normal echocardiogram does not exclude lethal arrhythmia, so echocardiography and serial QTc assessment are complementary rather than interchangeable. Prospective studies with advanced imaging are needed to establish phenotype frequency and determinants.